source
- Phase III trial shows tebentafusp doubles five-year survival in untreated metastatic uveal melanomaA Phase III study of tebentafusp in patients with previously untreated metastatic uveal melanoma reported that five-year overall survival was roughly twice that of the control group. The trial als…
- MRI Features That Suggest Diffuse Midline Glioma Highlighted in Expert DiscussionIn a recent educational segment, Dr. Chong introduced the clinical scenario where patients with suspected brain tumors are first evaluated with imaging before tissue sampling. He then asked Dr. Sh…